Clinical outcomes in ER+ HER2-negative breast cancer (BC) where treatment decisions incorporated the 21-gene recurrence score (RS): Elderly (≥70 yrs) vs younger patients (Pts).
Salomon M. Stemmer(Tel Aviv University), David Geffen(Ben-Gurion University of the Negev), Debbie McCullough(Genomic Health (United States)), Georgeta Fried(Roche (Switzerland)), Lior Soussan‐Gutman(Teva Pharmaceuticals (Israel)), Nicky Liebermann(Clalit Health Services), Steven Shak(Genomic Health (United States)), Shulamith Rizel(Rabin Medical Center), Noa Ben Baruch(Kaplan Medical Center), Bella Kaufman(NYU Langone Health), Avital Bareket‐Samish, Tamar Peretz(Hadassah Medical Center), Christer Svedman(Genomic Health (United States)), Kevin Isaacs(Emek Medical Center), Mariana Steiner(Sheba Medical Center), Bella Nisenbaum(Meir Medical Center), Shmuel Klang(Hebrew University of Jerusalem), Larisa Ryvo(Tel Aviv Sourasky Medical Center), Jamal Zidan(Rebecca Sieff Hospital), Ora Rosengarten(Sheba Medical Center)
Cited by 0
Related Papers
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
|Annals of Oncology|2020|1.4k
4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
|Annals of Oncology|2018|1.2k